PROVAYBLUE (methylene blue 0.5%) injection USP – Important Drug Warning letter to health care providers (2024)

Government Record · Provepharm (marketing authorisation holder) · January 10, 2024

Provepharm (marketing authorisation holder), 2024-01-10: Manufacturer safety letter restating the serotonin-syndrome boxed warning and warning that non-approved uses such as surgical or lymphatic visualisation carry a heightened risk of adverse events. It is a dated industry safety communication about off-label use.

The use of any available methylene blue product as a visualization aid during or after surgery, or as a dye for the visualization of lymphatic or other tissues is not FDA-approved and may also involve a heightened risk of adverse events.

p. 1

Provepharm (marketing authorisation holder), 2024-01-10: Manufacturer safety letter restating the serotonin-syndrome boxed warning and warning that non-approved uses such as surgical or lymphatic visualisation carry a heightened risk of adverse events. It is a dated industry safety communication about off-label use. Industry drug warning letter (PDF, 1 page verified as application/pdf). Issuer: Provepharm, marketing authorisation holder for PROVAYBLUE. Content: methylene blue is a reversible MAOI; concomitant serotonergic drugs and opioids risk serious or fatal serotonin syndrome; if IV use cannot be avoided use the lowest possible dose and observe up to 4 hours; non-approved visualisation uses may carry heightened risk. Note: the letter calls the product 'methylene blue 0.5%', equivalent to the 5 mg/mL strength in the label. Study type: regulatory record.